4594

BrightPath Biotherapeutics
4594

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
¥7.24B
EV
¥6.45B
Shares Outstanding
90.49M
Beta
1.17

Wall Street View

Analyst Rating
NOT_AVAILABLE
Analyst Target Price
-
P/E 2019E
-
P/Revenue 2019E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About BrightPath Biotherapeutics Co., Ltd.

gainify
4594

BrightPath Biotherapeutics Co., Ltd.

4594

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Pha...

Sector

Healthcare

Industry

Biotechnology

CEO

Nagai, Kenichi

Employees

42

IPO Date

2015-10-22

Headquarters

Kojimachi Central Building, 7th Floor, 2-2-4 Kojimachi, Chiyoda-ku, Tokyo Japan

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.